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Mu-opioid receptor (MOPr) agonists, such as morphine and its derivatives, are the
most effective and commonly used analgesics to treat acute pain. However, the utility of
morphine for the treatment of chronic pain is restricted due to the development of tolerance
to its analgesic efficacy over time and the development of withdrawal upon cessation of the
treatment. Morphine works by activating the MOPr within the descending pain modula-
tory pathway, which includes the periaqueductal gray (PAG), rostroventromedial medulla
(RVM), and the dorsal horn (DH) of the spinal cord to change how the body responds to
pain. The PAG has been found to be especially important in the development of morphine
tolerance. Our recent research has shown that a newly characterized G protein-coupled re-
ceptor, GPR171, was highly expressed in the PAG and modulated morphine antinociception
and opioid signaling. The main focus of this research was to explore the functional inter-
action of GPR171 in the effects of morphine induced tolerance and withdrawal to evaluate
this receptor’s function during chronic morphine treatment. Our results demonstrate that
activation of GPR171 with an agonist attenuates morphine tolerance in female mice. Most
importantly, GPR171 agonist in combination with morphine does not exacerbate morphine
induced tolerance and withdrawal during long term morphine treatment. Taken together,
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the results of this study suggest that this drug combination could possibly be used as a




The Role of the Recently Deorphanized G-protein Coupled Receptor, GPR171, in
Morphine Tolerance and Withdrawal
Leela Afrose
Opioid analgesics, such as morphine, represent the gold standard pain killer and the
most frequently used drugs for the treatment of moderate to severe pain. Despite being
a potent analgesic, morphine has unwanted and dangerous side effects with repeated use,
such as tolerance and withdrawal. Tolerance is a state when a person no longer responds to
a drug and a higher dose is required to achieve the same initial pain relief. Withdrawal is a
set of undesirable psychological and physiological symptoms that occur after someone stops
taking a drug or reduces the dose. Morphine tolerance and withdrawal play a vital role in
the development of opioid addiction. One of the crucial goals to reduce opioid addiction
is to develop pain therapeutics for chronic pain with high efficacy and reduced side effects.
Despite centuries of extensive research, the existing treatments for chronic pain have met
with limited success and developing better and alternative therapies are urgently needed.
A novel G-protein coupled receptor, GPR171, is found to be highly expressed throughout
the pain modulating regions of the brain. Our previous study found that activating this
receptor with an agonist, enhances morphine’s pain relieving property in combination ther-
apy during acute treatment in mice. In this study, we investigated the effects of activating
this receptor during long-term morphine treatment to evaluate tolerance and withdrawal.
Our results demonstrate that, activating this receptor reduces morphine induced tolerance
in female mice (but not males) on a thermal pain test and it does not have any additional
adverse effects on morphine tolerance and withdrawal syndrome. These results suggest the
potentiality of GPR171 as a novel pain therapeutics in combination with morphine with
vi
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assay or (B) hot plate (50◦C) assay. (A) On the tail flick assay, MS15203
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Day 5 using a cumulative quarter log dose procedure of morphine (1, 1.8,
3.2, 5.6,10, and 18 mg/kg, s.c.). Repeated injections of MS15203+Morphine
significantly increased tail flick latency compared to morphine alone, thus re-
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in tolerance in male mice (B) after repeated injection of MS15203+Morphine.
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Chronic pain costs approximately $635 billion annually which is greater than the com-
bined annual costs of heart disease, cancer, and diabetes in the United States (Gaskin &
Richard, 2012). Approximately 11% of the U.S. population suffer from daily pain (Nahin,
2015). In addition, pain is more prevalent in vulnerable subpopulations, including the
women, elderly, and socioeconomically challenged population (Green, Baker, Smith, & Sato,
2003). Chronic pain is associated not only with the complex web of heterogeneous illnesses
and injuries, but also with the treatment of disease. For example, most patients with
chronic pain related to cancer have pain related to chemotherapy, radiation therapy, and
surgery. Besides physical suffering, chronic pain patients suffer psychologically, emotionally,
and socially because of poor quality of life, and lost productivity. Management of chronic
pain is considered as one of the pivotal issues in public healthcare with currently available
analgesics because of its unclear etiology (Cherubino, Sarzi-Puttini, Zuccaro, & Labianca,
2012). Despite opioids being commonly prescribed, unwanted side effects, poor analgesic
efficacy over time and the growing opioid epidemic limit the effectiveness of opioid anal-
gesics specially for chronic pain. Our current health care system struggles with uncertainties
when treating a chronic pain patient in the face of opioid epidemic as well as the morbidity
and mortality associated with opioid overdose. Creating safer and better alternative pain
therapeutics than opioids is a dire need.
1.2 G Protein-Coupled Receptors as Pain Therapeutics
Around 35% of all FDA approved drugs act by targeting the G protein-coupled recep-
tors (GPCRs) (Insel et al., 2019). GPCRs are considered to be therapeutic targets due to
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their high number of cell surface expression and their ability to modulate many pathophys-
iological processes, including pain. Their critical roles in processing physiological functions
makes them an attractive target for developing pain medication. Studies have shown that
there are at least 40 members of the GPCR family that are considered to be potential thera-
peutic targets for the regulation of pain (Stone & Molliver, 2009). The agonists of Mu-opioid
receptor (MOPr), which is a G protein-coupled receptor, have been used for decades as an
effective pain killer. However, side-effects associated with their use limit the clinical ben-
efits of these drugs. Some of the most advanced efforts to develop safer pain treatments
have been focused on alternative GPCR targets, for example cannabinoids. Orphan re-
ceptors, a class of G protein-coupled receptors with unknown endogenous ligands, are an
unexplored avenue for developing new therapeutics (Nourbakhsh, Atabaki, & Roohbakhsh,
2018). Recently it has been identified that ProSAAS derived peptide, BigLEN, is the en-
dogenous ligand for the previously orphan G protein-coupled receptor, GPR171 (Gomes et
al., 2013). Various smaller peptides including little SAAS, PEN and BigLEN are derived
from ProSAAS (Mzhavia et al., 2002). ProSAAS is one of the most abundant pro-peptides
in the brain (Fricker, 2010) and has been implicated in a wide range of functions (Wei et
al., 2004; D. J. Morgan et al., 2010; Hoshino et al., 2014). Recently, ProSAAS was found to
be upregulated in cerebrospinal fluid in fibromyalgia patients (Khoonsari et al., 2019) indi-
cating that it may be involved in chronic pain. Little is known about the BigLEN-GPR171
neuropeptide receptor system’s function except for its role in anxiety (Bobeck et al., 2017)
and feeding behaviors (Wardman et al., 2016). In addition, our recent study found that
GPR171 modulates opioid induced signaling and antinociception (McDermott et al., 2019).
The goal of this current study was to evaluate the effect of GPR171 activation on morphine
tolerance and withdrawal to determine the potentiality of this receptor for developing new
therapeutics to treat pain.
1.3 Descending Pain Pathway and Opioid Function
The descending pain modulatory pathway includes the periaqueductal grey (PAG), the
rostral ventromedial medulla (RVM), and the dorsal horn (DH) of the spinal cord (Lueptow,
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Fakira, & Bobeck, 2018). These structures together take part in a mechanism through
which cortical and subcortical sites modulate nociception. Majority of the analgesic drugs,
including opioids target the descending pain modulatory system to relief pain (Ossipov,
Dussor, & Porreca, 2010). The PAG integrates information received from higher centers
of the brain and is capable of activating a powerful analgesic effect. The RVM, on the
other hand, facilitates or inhibits nociceptive inputs and acts as the final relay station in
the control of descending pain modulation (Ossipov, Morimura, & Porreca, 2014). Opioid
analgesics, such as morphine, produce their antinociceptive effects in part by inhibition
of neurons projecting from the PAG to the RVM, which in turn inhibits incoming pain
signals at the dorsal horn of the spinal cord (Heinricher, Tavares, Leith, & Lumb, 2009; Lau
& Vaughan, 2014). Many studies have highlighted the importance of the PAG in opioid
antinociception, tolerance, and withdrawal (Behbehani, 1995; Hao et al., 2011; Bobeck,
Haseman, Hong, Ingram, & Morgan, 2012). Chronic morphine produces downstream effects
and neuroadaptations along the descending pain pathway (Vanderah et al., 2001). The
Allen Brain Atlas shows high mRNA expression of both the BigLEN peptide and GPR171
in the descending pain modulatory pathway including the PAG. In addition, we found that
GPR171 is expressed in the PAG using immunohistochemistry (McDermott et al., 2019)
The ubiquitous expression of this neuropeptide and receptor in the descending pain pathway
make it likely for it to regulate morphine antinociception, tolerance and withdrawal.
1.4 Opioid Tolerance and Withdrawal
Despite being one of the most potent analgesics to date, morphine produces tolerance
and withdrawal syndromes when used repeatedly for a long period of time. Tolerance is
a state when a person stops responding at the current dose after repeated exposures and
a higher dose of the drug is needed to produce the same initial effects, resulting in dose
escalation (Chu, Clark, & Angst, 2006). Preclinical studies have established that chronic
administration of morphine produce a progressive increase in the ED50 over time (Way,
Loh, & Shen, 1969). In clinical settings, more than 10-fold dose escalations of opioid
dose are reported to treat chronic pain patients (Buntin-Mushock, Phillip, Moriyama, &
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Palmer, 2005). Opioids should be administered in an amount sufficient to achieve analgesia,
however, greater adverse effects are associated with a higher dose which poses a challenge
for the clinicians. One theory of morphine tolerance is linked to regulations of MOPr
desensitization, internalization, and downregulation (Al-Hasani & Bruchas, 2011; Williams
et al., 2013; Allouche, Noble, & Marie, 2014). It is well established that chronic morphine
treatment upregulates the cAMP-PKA signaling and leads to adaptations in many signaling
proteins within the descending pain modulatory pathway (Sharma, Klee, & Nirenberg, 1975;
Guitart & Nestler, 1989; Gintzler, Chakrabarti, & Dray, 2004). Despite significant amount
of research, the cellular and molecular mechanisms mediating the development of opioid
tolerance remain unclear and controversial.
Prolonged use of morphine in higher doses develops physical and psychological depen-
dence. Once the users stop taking morphine, they go through a severe withdrawal and want
to keep using morphine to feel normal. This is one of the reason people misuse morphine
and become addicted (Burma, Kwok, & Trang, 2017). The severity of opioid dependence
and withdrawal syndromes are considered as one of the major contributors to the addictive
potential of opioid narcotics. Once someone become dependent to morphine, withdrawal
syndrome is observed spontaneously upon the cessation of morphine after chronic use or
precipitated through the administration of an opiate antagonist both in human and rodents.
The symptoms develop within 24 hours of the cessation of morphine and persist for a week
or longer in human. The signs and symptoms of withdrawal in humans include diarrhea,
increased heart rate and blood pressure, insomnia, anxiety, irritability and stomach and
muscle cramps (Kosten & George, 2002) whereas in rodents jumping, diarrhea, weight loss,
paw tremors, wet-dog shakes, hyper-reactivity, teeth chatter, abrupt weight loss, ptosis,
and lacrimation behaviors are observed (Laschka, Teschemacher, Mehraein, & Herz, 1976).
To assess the ability of different pharmacological manipulations to alleviate the presence
or intensity of these signs and symptoms are used as a measure of their potential in the
treatment of opiate dependence.
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1.5 Morphine Tolerance and Withdrawal in the PAG
Several previous studies have demonstrated that after chronic exposure to morphine,
tolerance and dependance develop as a result of multiple signaling proteins and neural sys-
tem adaptation. For review see (Lueptow et al., 2018). Morphine induced tolerance is
largely linked to changes in the GABAergic neurons within the PAG (M. M. Morgan, Clay-
ton, & Lane, 2003). Repeated microinjection of morphine into the PAG develops tolerance
(M. M. Morgan, Clayton, & Boyer-Quick, 2005) and blocking of mu opioid receptors within
the ventrolateral PAG inhibit the development of morphine tolerance (Lane, Patel, & Mor-
gan, 2005). Another study observed that repeated microinjection of morphine within the
ventrolateral PAG caused a significant increase in Extracellular-Signal Regulated Kinase
1/2 (ERK1/2) and enhanced the development of morphine tolerance (Macey et al., 2009).
Inhibition of adenylyl cyclase within the ventrolateral PAG leads to a reduction in morphine
tolerance (Bobeck, Chen, Morgan, & Ingram, 2014). These findings suggest that the PAG
is particularly important in the regulation of morphine tolerance.
In rodent models, several brain regions are implicated to the physical signs of opiate
withdrawal including the PAG, locus coeruleus, nucleus accumbens, ventral tegmental area,
hypothalamus, amygdala and the spinal cord (Couceyro & Douglass, 1995; McPhie & Barr,
2009). Among the brain regions implicated in opiate dependence and withdrawal, the role
of the ventrolateral PAG appears to be one of the critical areas in the expression of many
withdrawal signs evident by biochemical and in vivo studies (Maldonado, Stinus, Gold, &
Koob, 1992; Stornetta, Norton, & Guyenet, 1993; Chieng, Keay, & Christie, 1995). A num-
ber of studies show alterations in c-fos immunoreactivity (Chieng et al., 1995) and changes
in intracellular recordings into the ventrolateral PAG after opioid withdrawal (Chieng &
Christie, 1996). The Tumor Necrosis Factor alpha (TNFα) and glial activation within the
PAG also take part in modulating withdrawal responses as has been reported by others
(Hao et al., 2011). Taken together, these data suggest that the PAG performs a key role in
the development of morphine tolerance and withdrawal.
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1.6 Sex Differences in Pain, Opioid Analgesia, Tolerance and Withdrawal
There is increasing evidence that chronic pain is more prevalent among female com-
pared to male patients due to biological, psychological and sociocultural factors (Fillingim,
King, Ribeiro-Dasilva, Rahim-Williams, & Riley, 2009; Bartley & Fillingim, 2013). A
number of studies have demonstrated that females have greater pain sensitivity and lower
response of analgesic drugs compared to males in both human and rodents (Cicero, Nock, &
Meyer, 1996; Bartok & Craft, 1997; Wiesenfeld-Hallin, 2005). Several rodent studies have
shown that male rodents produce greater stress-induced analgesia and tend to have a higher
response to MOPr agonists, such as morphine, compared to female rodents (Cicero et al.,
1996; Zubieta et al., 2002). Male rats show higher levels of MOPr expression and binding
than female rats within the PAG (Loyd, Wang, & Murphy, 2008). Another article reports
that females have greater morphine potency but slower onset and offset of analgesic effect
compared to males (Sarton et al., 2000). In addition, emerging evidence suggests that
sex hormones have numerous influences in pain sensitivity. Sex hormones and hormonal
levels are implicated in pain sensitivity and opioid tolerance with different stages of the
menstrual cycle (Kepler, Kest, Kiefel, Cooper, & Bodnar, 1989). A number of preclinical
studies have shown that males develop greater tolerance to morphine than females on the
hot plate (Badillo-martinez, Kirchgessner, Butler, & Bodnar, 1984), and tail flick (Mousavi,
Shafaghi, Kobarfard, & Jorjani, 2007). In addition, males have higher precipitated with-
drawal scores than females, indicating greater morphine dependence in males than females
(Kasson & George, 1984; Craft, Stratmann, Bartok, Walpole, & King, 1999). Research on
sex differences in morphine tolerance and withdrawal is still very limited and further study
is necessary to explain sex differences in morphine tolerance and dependence. Additional
exploration of these sex specific observation is required to determine these disparities in
gender biased pain mechanisms.
1.7 Purpose of Study
The goal of this research was to investigate the interactions of GPR171 and the opioid
system by using GPR171 small molecule ligands that were characterized previously using
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homology modeling and virtual screening (Gomes et al., 2013; Wardman et al., 2016; Bobeck
et al., 2017). Our previous data shows that GPR171 agonist, MS15203, and antagonist,
MS21570, do not have any antinociceptive effects on their own in male mice. In addition,
the GPR171 antagonist, MS21570, in combination with morphine causes a reduction in
antinociception and the agonist, MS15203, enhances morphine antinociception on the hot
plate and tail flick tests compared to morphine alone (McDermott et al., 2019). In this
study, we sought to investigate the cellular distribution of GPR171 within the PAG using
immunohistochemistry and the functional interaction of the GPR171 in morphine induced
tolerance and withdrawal in vivo. This study addressed three distinct levels of character-
ization: first, we sought to determine the colocalization of this receptor within different
neuronal subtypes in the PAG and our results show that the GPR171 is primarily found in
GABAergic neurons. Second, we evaluated the behavioral effects of this receptor agonist in
morphine tolerance by using the hot plate and tail flick behavioral assays in vivo and found
that this GPR171 agonist attenuates morphine tolerance in female mice on the tail flick
test and has no effect in male mice. Third, we set out to consider the role of GPR171 on
naloxone-precipitated withdrawal and our data reveals that this receptor has no influence
on morphine dependence and withdrawal. Taken together, these data suggest the possibility
of the GPR171 agonist to be safely combined with morphine treatment to reduce the dose
of morphine, therefore, making it a new novel area of study towards the development of
pain therapeutics with reduced side effects and abuse liability. The outcome of this study
is clearly an important step towards decoding this receptor’s interaction in opioid function
and the development of better and safer pain therapeutics and pain management modalities
for long term pain treatment1.





Male and female C57BL/6 mice (n = 236) (Charles River Laboratories, CA) were used.
Mice were 6-13 weeks old and weighing 13-27g at the beginning of the experiment. Mice were
housed (4–5 per cage) in a humidity and temperature-controlled room with a 12:12 hour
light/dark cycle (on 0700–1900) hours. Mice were handled for three days prior to testing. All
procedures were conducted in accordance with the guidelines by International Association
for the Study of Pain (IASP) and approved by the Utah State University Institutional Care
and Use Committee (Protocol #2775).
2.2 Distribution of GPR171 in the PAG
2.2.1 Fluorescence Immunohistochemistry
Male C57BL/6 mice (n = 5) were used. Immunohistochemistry was performed as
described previously (Wardman et al., 2016; Bobeck et al., 2017). Briefly, mice were deeply
anesthetized with Isoflurane and perfused transcardially through the ascending aorta with
4% paraformaldehyde. Collected brain tissues were postfixed for 1 hour and then stored
in 1X PBS. Immunohistochemistry was performed on free-floating coronal cut brain tissues
(50 µm) containing PAG. Sections were incubated in 1% sodium borohydride in 1X PBS
for 30 min followed by blocking buffer (5% normal goat serum and 0.3% Triton X-100 in
1X PBS) at room temperature for 1 hour. Tissues were incubated overnight at 4◦C in
primary antibodies against GPR171 (GeneTex, Irvine, CA) (rabbit, 1:400), glutamatergic
neurons (contain vglut2 immunoreactivity) (Millipore, Temecula, CA) (guinea pig, 1:500),
GABAergic neurons (contain GAD67 immunoreactivity) (Millipore, Temecula, CA) (mouse,
1:500), 1% Bovine Serum Albumin (Sigma-Aldrich) and 0.1% Triton X-100 (Sigma-Aldrich).
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Primary antibodies were visualized with goat anti-rabbit 594, goat anti rabbit 488, goat
anti-mouse 488 and goat anti-guinea pig 647 (Invitrogen, 1:1000) followed by 5 min of
incubation with the nuclear stain DAPI (100 ng/ml). Sections were then mounted with
ProLong Diamond Antifade (Invitrogen) (McDermott et al., 2019).
2.2.2 Microscopy and Image Analysis
Antibodies were detected by confocal microscopy at the Utah State University Mi-
croscopy CORE using Zeiss 710 Confocal Microscope by an experimenter blinded to the
experimental conditions. Images were processed using ImageJ (NIH), Excel (Microsoft)
and Prism software (version 7.0; GraphPad Software).
2.3 Role of GPR171 in Acute Morphine Administration
2.3.1 Drug Treatments
Male and female C57BL/6 mice (n = 119) were used. GPR171 agonist, MS15203
(10mg/kg, i.p., ChemBridge Co, and a gift from Sanjai Pathak, Queens College, NY),
GPR171 antagonist, MS21570 (5 mg/kg, i.p.; Santa Cruz Biotechnology, Inc., Santa Cruz,
CA), were diluted in 10% DMSO (Sigma- Aldrich, St. Louis, MO ) in Saline. Morphine
Sulfate (2 or 5mg/kg s.c., Hikma, London, UK) was suspended in 0.9% Saline. All drugs
were administered at a volume of 10 ml/kg. These doses were chosen based on previous
studies (Wardman et al., 2016; Bobeck et al., 2017). Mice were randomly divided into 8
groups: Vehicle + Morphine (5mg), Vehicle + Morphine (2mg), Vehicle + Saline, MS15203
+ Saline, MS15203 + Morphine (5mg), MS15203 + Morphine (2mg), MS21570+Morphine
(5 mg), MS21570 + Saline group. A power analysis was conducted to determine a sample
size of n = 8 based on preliminary studies (McDermott et al., 2019).
2.3.2 Time Course Paradigm
Mice were injected with MS15203 (10 mg/kg, i.p.), MS21570 (5 mg/kg, i.p.), or 10%
DMSO (10 ml/kg, i.p.) 10 minutes prior to injections of morphine (2 or 5 mg/kg, s.c.) or
10
saline (10 ml/kg, s.c.). All animals were tested on hot plate and tail flick tests prior to any
drug administration to assess baseline scores, and then at 15, 30, 60, and 120 minutes after
the second drug injection of morphine or saline (McDermott et al., 2019).
2.4 Role of GPR171 in Chronic Morphine Administration
2.4.1 Drug Treatments
Male and female C57BL/6 mice (n = 59) were used. GPR171 agonist, MS15203
(10mg/kg, i.p.), GPR171 antagonist, MS21570 (5 mg/kg, i.p.) were diluted in 10% DMSO in
Saline. Morphine sulfate (5mg/kg s.c.) was suspended in 0.9% saline. Mice were randomly
divided into 6 groups: DMSO + Morphine, DMSO + Saline, MS15203 + Saline, MS15203 +
Morphine, MS21570 + Morphine, MS21570 + Saline group. A power analysis was conducted
to determine a sample size of n = 8 based on preliminary tolerance studies.
2.4.2 Tolerance Induction and Dose Response Paradigm
On day 1, mice were injected with MS15203 (10 mg/kg, i.p.), MS21570 (5 mg/kg, i.p.),
or 10% DMSO (10 mL/kg, i.p.) 10 min prior to injections of morphine (5mg/kg, s.c.) or
equal volume of saline (10 mL/kg, s.c.). On Days 1-4, mice were injected with their specific
drug combination twice daily (10 AM and 4 PM) to induce morphine tolerance. On Day
5, Cumulative quarter log doses of morphine (to obtain final doses of 1, 1.8, 3.2, 5.6, 10,
and 18 mg/kg, s.c.) were administered at 30 min intervals, and mice were tested on the
hotplate and tail flick test 15 min after morphine/saline injection. These doses and injection
times were modified from known procedures that produce dose-dependent antinociception
in rats (Bobeck, McNeal, & Morgan, 2009; Bobeck et al., 2012, 2014) and in mice during
our preliminary studies.
2.5 Role of GPR171 in Morphine Withdrawal
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2.5.1 Drug Treatments
Male C57BL/6 mice (n = 53) were used. GPR171 agonist, MS15203 (10mg/kg, i.p.)
and GPR171 antagonist MS21570 (5 mg/kg, i.p.), was diluted in 10% DMSO in Saline.
Morphine sulfate (5 mg/kg, s.c.) was suspended in 0.9% saline. Mice were randomly
divided into 6 groups: DMSO + Morphine, DMSO + Saline, MS15203 + Saline, MS15203
+ Morphine, MS21570 + Morphine, MS21570 + Saline group.
2.5.2 Withdrawal Paradigm
On day 1, mice were injected with MS15203 (10 mg/kg, i.p.), MS21570 (5 mg/kg, i.p.)
or 10% DMSO (10 mL/kg, i.p.), 10 minutes prior to injections of morphine (5 mg/kg, s.c.)
or equal volume of saline (10 mL/kg, s.c.). Mice were injected twice daily (10 AM and 4
PM) with their designated drug combination for 4 days to induce morphine dependance.
On day 5, each mouse received their designated drug combination in morning only. Two
hours later they were given Naloxone Hydrochloride (2 mg/kg, i.p.; Tocris Bioscience) and
monitored and video recorded for counting the number of jumping for 30 min. Number
of jumps were observed and counted as withdrawal behavior. Jumping is considered as a
well-documented withdrawal behavior in mice (Kest et al., 2002).
2.6 Behavioral Tests
2.6.1 Hot Plate Test
Nociception was assessed using the hot plate (Harvard Apparatus, Holliston, MA).
The hot plate test involves higher brain function and is considered to be a supraspinally
organized response. We measured the latency for the mice to lick the hind paw when placed
on a 50◦C hot plate. To avoid tissue damage, mice were removed from the hot plate if no
response occurs within 60s.
2.6.2 Tail Flick Test
Thermal nociception was assessed with tail flick, warm water bath (Thermo Fisher
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Scientific) test. Tail flick test was conducted to observe spinal reflex. We measured the
tail-withdrawal latency of the mice using a 52◦C water bath. Cut off time was 20s to avoid
tissue damage.
2.7 Data and Statistical Analyses
Statistical analyses of data were conducted by using Microsoft Excel and Prism software
(version 7.0; GraphPad Software). Data were generated by one-way or two-way ANOVA
(repeated measures), when appropriate using Prism software. Dunnett’s or Tukey’s honestly




3.1 Distribution of GPR171 in the PAG
Fig. 3.1: GPR171 expression in different neuronal populations. (A) Image from mouse brain
atlas indicating location of PAG adapted from (Paxinos & Franklin, 2001). (B) Immuno-
histochemistry shows high expression of GPR171 in the PAG. (C) Immunohistochemistry
results show that GPR171 is colocalized with GAD67 (i.e., GABA neurons). There are
fewer cells that show colocalization of GPR171 and vGlut2. Data are representative of two
sections from four mice. Arrows indicate colocalization. Scale bars, 50 mm (McDermott et
al., 2019).
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We performed free floating fluorescence immunohistochemistry to investigate the ex-
pression of GPR171 within the PAG. We found that GPR171 is highly expressed in all areas
of PAG, especially the ventrolateral PAG, which has been implicated in pain modulation
(Fig. 3.1A and B). Fig. 3.1A is adapted from (Paxinos & Franklin, 2001). Our data shows
that GPR171 was primarily colocalized with GAD67 within the ventrolateral PAG. In addi-
tion, there was some colocalization of this receptor with vGLUT2 (Fig. 3.1C) (McDermott
et al., 2019). This data indicates that GPR171 is predominately expressed within the
GABAergic neurons within the ventrolateral PAG, it is also expressed in a subset of gluta-
matergic neurons.
3.2 GPR171 Ligands Do Not Produce Antinociception
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Fig. 3.2: Small molecule ligands targeting GPR171, alone do not produce antinociception
in males. GPR171 agonist (MS15203; 10 mg/kg, i.p.), GPR171 antagonist (MS21570; 5
mg/kg, i.p.), or vehicle (10% DMSO in saline, i.p.) were administered to mice and then
tested on the warm water (52◦C) tail flick assay (A) or hot plate (50◦C) assay (B) at 15,
30, 60, or 120 minutes. The data reveal no change in nociception on either test. Data are
the means ± S.E. of 8–12 animals/group (McDermott et al., 2019).
There was no statistically significant difference in the baseline tail flick [F (7, 79) =
1.16, P = 0.338] or hot plate [F (7, 79) = 0.877, P = 0.528] latencies between the groups
prior to starting the experiment. Administration of MS15203 + Saline or MS21570 + Saline
were not significantly different from the Vehicle + Saline group [F (2, 25) = 0.309, P = 0.737]
at any time point [F (4, 100) = 2.91, P = 0.253] on the tail flick test (Fig. 3.2A). Simi-
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larly, MS15203 and MS21570 groups were not different from the control group [F (2, 25) =
2.98, P = 0.069] at any time point [F (4, 100) = 1.55, P = 0.194] on the hot plate test
(Fig. 3.2B). These data suggest that GPR171 agonist or antagonist alone does not produce
antinociception (McDermott et al., 2019).
3.3 GPR171 Ligands Alter Morphine-Induced Antinociception
Fig. 3.3: GPR171 ligands alter morphine antinociception in male mice. GPR171 agonist
(MS15203; 10 mg/kg, i.p.), GPR171 antagonist (MS21570; 5 mg/kg, i.p), or vehicle (10%
DMSO in saline, i.p.) were administered 10 minutes prior to saline (10 ml/kg) or morphine
(Mor; 2 or 5 mg/kg, s.c.). Antinociception was evaluated at 15, 30, 60, or 120 minutes
on the warm water (52◦C) tail flick assay (A) or hot plate (50◦C) assay (B). GPR171
agonist, MS15203, does not alter morphine (5 mg)-induced antinociception while GPR171
antagonist decreased antinociception as measured on the tail flick assay. MS15203 increased
antinociception following the lower dose of morphine (2 mg). (B) On the hot plate test,
MS15203 increased 5 mg morphine-induced antinociception at 15, 30, and 60 minutes,
while MS21570+Mor (5 mg) does not induce antinociception greater than saline controls.
MS15203+Mor (2 mg) produced significant antinociception at 30 minutes, whereas Mor
(2 mg) did not. Inset: Dunnett’s post hoc to evaluate main effect compared with saline.
*P< 0.05; ***P< 0.001; ****P< 0.0001, compared with saline; #P< 0.05, compared with
morphine; @P < 0.05, compared with morphine + agonist. n.s., Not significant; HP, hot
plate; TF, tail flick. Data are the means ± S.E. of 8–15 animals/group (McDermott et al.,
2019).
On the tail flick test in male mice, there was no statistically significant difference in
the baseline tail flick latencies (Tukey’s, P > 0.05) between any group before starting the
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experiment. All morphine treated groups showed increased latencies [F (5, 65) = 29.12, P <
0.0001] across all time points [F (4, 260) = 122.5, P < 0.0001] compared to the saline treated
groups (Fig. 3.3A). There was an overall significant main effect between Vehicle + Morphine
(5 mg), MS15203 + Morphine (5 mg), MS15203 + Morphine (2 mg), and MS21570 +
Morphine (5 mg) compared with Vehicle + Saline treated mice (Dunnett’s, P < 0.05). The
agonist, MS15203 + Morphine (5 mg) group was not significantly different than the Vehicle
+ Morphine (5 mg) group on the tail flick test at any time point (Tukey’s, P > 0.05).
Given that the 5 mg morphine dose produced a maximal antinociceptive effect on the tail
flick test, another group of animals received 2 mg morphine in combination with MS15203.
MS15203 + Morphine (2 mg) group showed an increase in antinociception on the tail flick
test compared with saline group (Dunnett’s, P < 0.05), whereas Vehicle + Morphine (2
mg), did not produce significant anticonception compared with saline group (Dunnet’s,
P > 0.05). On the other hand, the antagonist, MS21570 + Morphine (5 mg) caused a
significant reduction in morphine antinociception compared with Vehicle + Morphine (5
mg) group at the 120-minute time point (Tukey’s, P < 0.05). (Fig. 3.3A).
A similar finding is seen in male mice on the hot plate test. There was no statistically
significant difference in the baseline hot plate latencies (Tukey’s, P > 0.05) between any
group before starting the experiment. Morphine treated groups showed increased hot plate
latencies [F (5, 65) = 8.94, P < 0.0001] over time [F (4, 260) = 35.51, P < 0.0001] (Fig. 3.3B).
There was an overall significant main effect between Vehicle + Morphine (5 mg), MS15203
+ Morphine (5 mg) and MS15203 + Morphine (2 mg) compared to Vehicle + Saline group
(Dunnett’s, P < 0.05). Vehicle + Morphine (5 mg) and MS15203 + Morphine (5 mg)
groups showed a significant increase in hot plate latencies compared to Vehicle + Saline
treated mice at the 15, 30, and 60 minute time points (Tukey’s, P < 0.05). Importantly,
MS15203 + Morphine (5 mg) treatment produced significantly greater antinociception than
Vehicle + Morphine (5 mg) at 30 min time point (Tukey’s, P < 0.05). However, MS21570
+ Morphine (5 mg) was not significantly different from the Vehicle + Saline group at any
time point (Tukey’s, P > 0.05), but was significantly different from MS15203 + Morphine
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(5 mg) at 15, 30, and 60 minutes (Tukey’s, P < 0.05). Similar to the tail flick result, 2 mg
morphine did not produce antinociception compared to saline controls (Tukey’s, P > 0.05).
However, MS15203 + Morphine (2 mg) produced a significant increase in hot plate latencies
compared to saline controls at the 30 minute time point (Tukey’s , P < 0.05) (Fig. 3.3B).
These results indicate that GPR171 agonist increases morphine induced antinociception on
the hot plate test, conversely, the antagonist reduces morphine antinociception on the tail
flick and hot plate tests (McDermott et al., 2019).













































Fig. 3.4: GPR171 agonist increased morphine antinociception in female mice on the tail flick
test. GPR171 agonist (MS15203; 10 mg/kg, i.p.) or vehicle (10% DMSO in saline, i.p.)
were administered 10 minutes prior to morphine (5 mg/kg, s.c.) or saline (10 ml/kg, s.c.)
injection. Antinociception was assessed at 15, 30, 60, or 120 minutes on the (A) warm water
(52◦C) tail flick assay or (B) hot plate (50◦C) assay. (A) On the tail flick assay, MS15203
enhanced morphine induced antinociception at 120 min time point. (B) On the hot plate
thermal assay, MS15203 induces greater, but not significant antinociception compared to
morphine treated mice. ***P< 0.001, n.s., Not significant. 7-9 animals/group.
Similar results were observed in female mice. There was no statistically significant
difference in the baseline tail flick and hot plate latencies (Tukey’s, P > 0.05) between
any group before starting the experiment. All morphine-treated groups showed increased
latencies on the tail flick test [F (3, 28) = 104.2, P < 0.0001] across time [F (4, 112) =
47.34, P < 0.0001] comparing to the saline treated groups. There was an overall signifi-
cant main effect between Vehicle + Morphine and MS15203 + Morphine compared with
Vehicle + Saline treated mice (Dunnett’s, P < 0.05). The agonist, MS15203 + Morphine
group was significantly different from the Vehicle + Morphine group at 120 min time point
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(Tukey’s, P < 0.05). But at the 15, 30, and 60 min time point it was not significant
(Tukey’s, P > 0.05) (Fig. 3.4A) indicating that MS15203 enhanced the duration of mor-
phine antinociception.
On the hot plate test, morphine-treated groups showed increased hot plate latencies
[F (3, 28) = 20.48, P < 0.0001] over time [F (4, 112) = 40.80, P < 0.0001] compared to
the saline treated groups. There was an overall significant main effect between Vehicle
+ Morphine and MS15203 + Morphine compared with Vehicle + Saline treated group
(Dunnett’s, P < 0.05). MS15203 + Morphine group showed increased, but not statistically
significant antinociception at any time point (Tukey’s, P > 0.05) compared to the Vehicle +
Morphine group (Fig. 3.4B). These data suggest that GPR171 agonist enhances morphine
antinociception on the tail flick but not on the hot plate test in female mice.
3.4 GPR171 Agonist Decreases Morphine Tolerance in Female on the Tail
Flick Test
In order to assess the role of MS15203 on the development of morphine tolerance and
to ascertain differences between groups a dose response on the tail flick and hotplate were
run concurrently. Morphine produced a dose-dependent increase in tail flick latencies for all
groups (Fig. 3.5A). Mice treated with twice-daily injections of morphine for 4 days were tol-
erant as seen by a rightward shift in the dose response curve compared to saline treated mice
on the tail-flick test in both female [F (3, 172) = 6.392, P < 0.0001] (Fig. 3.5A, Table 3.1).
and male mice [F (3, 166) = 38.40, P < 0.0001] (Fig. 3.5B, Table 3.1). Pretreatment with
MS15203 + Morphine significantly reduced ED50 values compared to DMSO + Morphine
group in female mice on the tail flick test which reveals a reduction in the development of
tolerance (Fig. 3.5A; see Table 3.1 to compare ED50 values). Conversely, pretreatment with
MS15203 + Morphine did not alter tolerance to morphine compared to DMSO + Morphine
group in male mice on the tail flick test (Table 3.1). MS15203 + Saline and DMSO + Saline
groups were not different in female mice. Notably, MS15203 + Saline group caused a right-
ward shift in the morphine dose response curve compared to DMSO + Saline group in male
mice (Fig. 3.5B), suggesting that repeated injection of MS15203 alone reduces morphine
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Fig. 3.5: GPR171 agonist attenuated morphine tolerance in female but not in male mice
on the tail flick test. Tolerance was induced by twice-daily injections of morphine for 4
days as seen by a rightward shift in the dose response curve compared to saline treated
mice. Dose response curves were performed on Day 5 using a cumulative quarter log dose
procedure of morphine (1, 1.8, 3.2, 5.6,10, and 18 mg/kg, s.c.). Repeated injections of
MS15203+Morphine significantly increased tail flick latency compared to morphine alone,
thus reducing morphine tolerance in female mice (A), while there was no difference in
tolerance in male mice (B) after repeated injection of MS15203+Morphine. Interestingly,
repeated injection of MS15203 alone did not produce any effect in female mice (A) whereas,
MS15203 decreased morphine analgesia compared to saline treated group in male mice (B).
5-8 animals/group.
Table 3.1: Comparison of ED50 Values
for Tail Flick Test
Treatment Females Males
DMSO+Saline 4.057 ± 0.3651∗ 6.819 ± 0.4904∗
DMSO+Morphine 6.770 ± 0.6899@ 30.46 ± 8.494@
MS15203+Saline 3.367 ± 0.3710∗ 9.264 ± 1.926@∗
MS15203+Morphine 4.256 ± 0.5710∗ 22.46 ± 3.649@
@p < 0.05 from saline treated mice; *p < 0.05 from morphine treated mice.
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3.5 GPR171 Agonist Does Not Alter Morphine Tolerance in Either Male or
















































Fig. 3.6: GPR171 agonist did not alter morphine tolerance in female or male mice on the
hot plate test. Tolerance was induced by twice-daily injections of morphine for 4 days as
seen by a rightward shift in the dose response curve for DMSO+Morphine group compared
to DMSO+Saline group in male (B), but not in female mice (A). Dose response curves were
performed on Day 5 using a cumulative quarter log dose procedure of morphine (1, 1.8, 3.2,
5.6, 10, and 18 mg/kg, s.c.). The data reveals that pretreatment with MS15203+Morphine
produced a rightward shift similar to DMSO+Morphine, suggesting that morphine tolerance
is not affected by repeated administration of MS15203 in female (A) and male (B) mice
during hot plate thermal pain assay. Interestingly, repeated administration of MS15203
alone on Day 1-4 caused an increase in morphine induced antinocieption on Day 5 in both
female (A) and male (B) mice. 5-9 animals/group.
Table 3.2: Comparison of ED50 Values
for Hot Plate Test
Treatment Females Males
DMSO+Saline 6.584 ± 0.8422 10.65 ± 0.6109∗
DMSO+Morphine 7.781 ± 0.6273 14.55 ± 0.7941@
MS15203+Saline 4.387 ± 0.9597@∗ 7.321 ± 0.7588@∗
MS15203+Morphine 7.886 ± 0.4549 14.13 ± 0.9023@
@p < 0.05 from saline treated mice; *p < 0.05 from morphine treated mice.
Mice treated with twice daily injections of morphine for 4 days were tolerant on the
hot plate test as seen by the rightward shift in the dose response curve compared to saline
treated male mice [F (3, 178) = 16.43, P < 0.0001] (Fig. 3.6B; Table 3.2). Female mice
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treated with 4 days morphine injection did not show morphine tolerance on the hot plate test
[F (3, 178)4.025, P = 0.0084] (Fig. 3.6A; Table 3.2). There was a significant dose-dependent
increase in hot plate latencies for all female groups comparing to the saline treated mice.
Pretreatment with MS15203 + Morphine did not alter ED50 values compared to DMSO +
Morphine group suggesting that morphine induced tolerance was not affected by repeated
administration of the GPR171 agonist, MS15203, on the hot plate test in either male or
female mice (Fig. 3.6). MS15203 + Saline group showed a reduction in ED50 values com-
pared to DMSO + Saline group in both sexes (Table 3.2) suggesting that repeated injection
of MS15203 alone enhances morphine antinociception. ED50s are presented in Table 3.2.


















































Fig. 3.7: Pretreatment with GPR171 agonist did not alter withdrawal behaviors in male
mice. Animals were treated with GPR171 agonist, MS15203 (10 mg/kg, i.p.) or vehicle
(10% DMSO in saline, i.p.) 10 minutes before morphine (5 mg/kg, s.c.) or saline (10 ml/kg,
s.c.) injection twice daily for 4 days to induce morphine dependence. On day 5, mice were
treated with their designated drug combination. Two hours later Naloxone Hydrochloride (2
mg/kg, i.p.) was administered to induce precipitated withdrawal. Mice were video recorded
immediately for 30 minutes to observe withdrawal behavior- jumping. Repeated injection of
DMSO + Morphine caused an increase in jumping number compared to the DMSO + Saline
treated mice indicating that those mice developed morphine dependence. Administration
of MS15203 + Morphine did not alter jumping number comparing to the morphine treated
group. Administration of MS15203 + Saline increased the jumping number compared with
the saline treated mice, although the increase is not significant. *P < 0.05, compared with
saline. Data are the means ±SEM. 8–10 animals/group.
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Mice treated with twice-daily injections of morphine for 4 days showed morphine de-
pendence by significant increase in jumping compared to the DMSO + Saline treated mice
(Tukey’s, P < 0.05). Administration of MS15203 + Morphine did not alter jumping com-
pared to the DMSO + Morphine treated group (Tukey’s, P > 0.05), suggesting that
GPR171 agonist, MS15203, does not have any effect on morphine withdrawal (Fig. 3.7).
Repeated administration of MS15203 + Saline did not produce a significant change in the




In this present study, we investigated the expression of GPR171 within the PAG and
its ability to modulate morphine antinociception, tolerance, and withdrawal in male and
female mice. We found that GPR171 is primarily expressed in GABAergic neurons in the
PAG. Consistent with our previous findings in male mice, we found that MS15203 enhances
morphine antinociception in female mice (McDermott et al., 2019). Our data also demon-
strate that pretreatment with GPR171 agonist, MS15203, attenuates morphine tolerance
on the tail flick test in female mice while having no effects in male mice. Interestingly,
repeated injection of MS15203 alone enhanced morphine antinociception on the hot plate
test in both sexes. In contrast, MS15203 did not alter morphine tolerance on the hot plate
test in either sex. Furthermore, female mice did not show any morphine tolerance on the
hot plate test. The result of our withdrawal study suggests that GPR171 agonist, MS15203,
treatment does not alter morphine dependence or withdrawal.
4.1.1 GPR171 is Found in GABAergic Neurons
Given that the neurons in the ventrolateral PAG primarily contribute to morphine
antinociception and tolerance, we performed immunohistochemistry to observe the colo-
calization of GPR171 with the neuronal subtypes in this region. We found that GPR171
is mainly found within GABAergic neurons. It is also found in a smaller number of glu-
tamatergic neurons. Several previous studies suggest that under normal conditions, the
GABAergic interneurons in the PAG have tonic activity, thereby causing a steady release
of GABA and inhibition of PAG output neurons. However, upon binding of opioids to the
MOPr within the PAG, the activity of GABAergic neurons are decreased, resulting in an
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increase in activity of the PAG output neurons to the RVM (Vaughan, Ingram, Connor, &
Christie, 1997; Bobeck et al., 2014). This increased activity from the PAG to the RVM is
considered as the main contributor to the opioid-induced antinociception, by blocking in-
coming pain signals in the spinal cord. In addition, both in vitro (Chieng & Christie, 1994;
Bobeck et al., 2014) and in vivo (M. M. Morgan & Liebeskind, 1987; Tortorici, Robbins,
& Morgan, 1999) studies have linked alterations within these PAG GABAergic neurons in
morphine tolerance. It has been proposed that blocking the MOPr within the PAG, in-
hibits the development of tolerance following systemic morphine injection and inactivation
of the RVM by a GABA agonist along with microinjection of morphine into the PAG, still
leads to the development of tolerance in rats (Lane et al., 2005). These data suggest that
morphine tolerance is primarily associated with a decrease in opioid mediated inhibition
of GABA release within the ventrolateral PAG. It is possible that the GPR171 located on
these GABAergic neurons regulate morphine antinociception and tolerance. Although the
underlying mechanism warrants further research.
4.1.2 GPR171 Agonist Increases Morphine Antinociception
Our recent study has demonstrated that GPR171 agonist, MS15203, enhances mor-
phine antinociception, whereas antagonism of this receptor decreases morphine antinoci-
ception during acute morphine treatment (McDermott et al., 2019). Given that we tested
only male mice in our previous study, here in this study, we performed a time course to
observe the effects of MS15203 on acute morphine antinociception in female mice. We found
that MS15203 enhances morphine antinociception both on the tail flick and hot plate test in
female mice, which is consistent with our previous findings in male mice. Although the in-
crease in hot plate latencies is not statistically significant compared to the morphine treated
group. Overall, these data suggest that GPR171 agonist, MS15203, enhances morphine-
induced antinociception on spinal and supraspinal measures in both sexes.
On the hot plate assay, repeated administration of MS15203 alone led to increased
latencies in both sexes. Our previous study reports that acute administration of MS15203
does not have any analgesic property on its own (McDermott et al., 2019). However,
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we did not look at the analgesic effects of repeated injection of MS15203. It should be
noted that the morphine dose-response study was performed at least 12 hours after the
last injection, which suggests that MS15203 was likely not active in the bloodstream. A
similar effect of MS15203 administration is also observed on the tail flick test in female mice
although not significant comparing to saline treated groups. However, an opposite result
is observed in male mice meaning that repeated injection of MS15203 decreased morphine
antinociception. It is unclear why this effect of repeated MS15203 treatment would be
different on the two tests. The pharmacokinetics and pharmacodynamics of MS15203 are
unknown, which could contribute to the differences in its effects in the brain versus spinal
cord. However, it has been shown that MS15203 crosses the blood brain barrier and activates
neurons in the hypothalamus (Wardman et al., 2016). Our hypothesis is that repeated
administration of MS15203 leads to enhanced downstream signaling which in turn causes
enhanced morphine antinociception. Our previous study shows that blockade of GPR171
decreases MOPr mediated G protein activity in vitro (McDermott et al., 2019). In this
present study, we only investigated the behavioral aspects of the function of MS15203.
Further studies are needed to interpret the cellular changes of underlying mechanisms.
4.1.3 Development of Morphine Tolerance is Reduced in Female Mice on the
Hot Plate Test
In this study we found that female mice developed less morphine tolerance compared
to the male mice on the hot plate assay. Previous literature on sex differences in morphine
tolerance are controversial and have reported mixed findings. A number of studies have
found that females are less tolerant to morphine than males (Badillo-martinez et al., 1984;
Craft et al., 1999; South, Wright, Lau, Mather, & Smith, 2001), where other studies show
no sex difference in tolerance in rats (Thornton & Smith, 1997; Holtman, Sloan, & Wala,
2004). It has been shown that chronic administration of systemic morphine induces greater
tolerance in male than in female rats (Loyd, Morgan, & Murphy, 2008). The greater
sensitivity of males to acute morphine analgesia could account for the greater tolerance
observed in male rats. Likewise, female rats develop tolerance against morphine to a lesser
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extent and slower than male rats (Barrett, Cook, Terner, Craft, & Picker, 2001). It should
be noted that female rats differ in the degree of morphine tolerance in particular phase of the
estrous cycle (Shekunova & Bespalov, 2004). However, we did not attempt to examine the
estrous cycle phase of the female mice in this current experiment. One possible mechanism
for the dissimilar tolerance development observed in female mice on the tail flick and hot
plate test may be explained by the supraspinal versus spinal nature of the two tests. The
hot plate test is a supraspinal pain assay while tail-flick measures a spinal reflex. These two
methods predominantly reflect nociception and tolerance at different levels of the central
nervous system. In addition, repeated testing of mice using the hot plate has a learning
component which the mice learn to exhibit certain behaviors so that they can be quickly
removed from the hotplate apparatus (Chapman et al., 1985; Le Bars D, Gozariu M, 2001).
This learning phenomenon can confound the results on the hot plate test. It should be noted
that female mice developed morphine tolerance to a lesser extent both on the hot plate and
tail flick test compared to the male mice in this current study. On the hot plate test, male
mice showed 2-fold shift in the ED50, whereas female mice showed no difference comparing
to the saline treated group. On the tail flick test, male and female mice showed 5-fold
and 2-fold shift in the ED50 values respectively compared to the saline group. Considering
all these above-mentioned factors, it can be said that this female specific lack of tolerance
development might be a result of many associated factors.
4.1.4 Combined Treatment of GPR171 Agonist and Morphine Decreases Tol-
erance in Female Mice
Our data shows that activation of GPR171 with the agonist, MS15203, reduced mor-
phine induced tolerance in female mice on the tail flick test. A similar trend is observed in
male mice showing that the ED50 is in between saline and morphine treated groups, but not
significant from morphine. These results are consistent with our previous data where injec-
tion of MS15203 in combination with morphine enhanced analgesia during acute morphine
treatment in both male (McDermott et al., 2019) and female mice in the current study.
Given that MS15203 increases morphine’s pain-relieving property during acute treatment,
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MS15203 leads to a corresponding progressive increase in morphine analgesia during re-
peated administration of MS15203 + Morphine, resulting in enhanced morphine function
or decreased morphine tolerance. Our immunohistochemistry data shows that GPR171 is
expressed on the GABAergic neurons of PAG. It is evident that MOPr are also located on
the GABAergic neurons of PAG (Stiller, Bergquist, Beck, Ekman, & Brodin, 1996; Lueptow
et al., 2018). Due to the co-expression of these two receptors in the GABAergic neurons of
the PAG, activation of these two receptors together inhibit the GABA release to a greater
extent than morphine alone. Thereby, increasing morphine antinociception during acute
treatment and in parallel, decreasing morphine tolerance during chronic treatment are ob-
served. Interestingly, our results show that MS15203 does not alter morphine tolerance in
male mice on the hot plate test. One plausible explanation is that GPR171 is more prevalent
in the periphery and modulating morphine tolerance at the peripheral level that contributes
primarily to the spinal sites to the development of tolerance rather than the supraspinal
sites. Taken together, these results indicate that combined treatment of GPR171 agonist,
MS15203 and morphine does not have any adverse effect on morphine tolerance. This
combination therapy has the potential to reduce morphine dose, thereby attenuating tol-
erance and dependence to morphine during long-term treatment. Most importantly, this
combination therapy is likely to reduce morphine tolerance in female.
4.1.5 GPR171 Agonist Has No Effect on Morphine Withdrawal
Our withdrawal experiment result shows that MS15203 does not alter morphine with-
drawal induced jumping. We only explored the effects of the GPR171 agonist, MS15203,
on morphine withdrawal in male mice. Given that MS15203 has no effect on morphine
tolerance, it is not surprising that it does not regulate morphine withdrawal in male mice.
Multiple brain regions are found to be involved in morphine withdrawal including the PAG,
locus coeruleus, nucleus accumbens, ventral tegmental area, hypothalamus, frontal cortex,
amygdala and the spinal cord (McPhie & Barr, 2009). Although the PAG is thought to per-
form a key role in morphine withdrawal (Ouyang et al., 2012), other studies have highlighted
the role of locus coeruleus, ventral tegmental area (McClung, Nestler, & Zachariou, 2005)
28
and frontal cortex (Ammon, Mayer, Riechert, Tischmeyer, & Höllt, 2003) as the primary
contributor of morphine withdrawal symptoms. By immunohistological analysis, we only
explored the expression of GPR171 within the PAG, while the expression of this receptor
in other areas is still unknown. A likely explanation to our observation is that morphine
withdrawal is mediated largely by the areas other than PAG and that is why MS15203 has
no influence on this phenomenon. Additionally, It has been reported that the glutamatergic
neurons are involved in naloxone-precipitated withdrawal symptoms (Zhang et al., 2020).
Our immunohistochemistry data shows that the GPR171 is primarily colocalized with the
GABAergic neurons and, to a lesser extent, in glutamatergic neurons of PAG. Given that
this receptor is not highly expressed on the glutamatergic neurons, activation of this re-
ceptor might not have any effect on morphine withdrawal. It is evident that although Mu
opioid receptor agonist, morphine inhibits adenylyl cyclase activity during acute treatment
(Fedynyshyn & Lee, 1989), there is a compensatory increase in adenylyl cyclase signaling
during chronic treatment with morphine causing an increased neuronal adenylyl cyclase
activity, thereby cAMP is upregulated during withdrawal (Terwilliger, Beitner-Johnson,
Sevarino, Crain, & Nestler, 1991). The GPR171 agonist, MS15203, works in a similar fash-
ion as morphine meaning that it also reduces cAMP production. It is possible that the
reduction in the adenylyl cyclase signaling by GPR171 is not potent enough to attenuate
morphine tolerance or withdrawal. In this study, we used relatively lower doses of morphine
(5mg/kg) and naloxone (2mg/kg), where other researchers have used higher or escalating
doses of morphine and a wide range of naloxone doses (Kasanga et al., 2017). As a sign of
withdrawal behavior, only jumping number was observed in this study. Although jumping
is a well-documented withdrawal behavior in mice (Kest et al., 2002), other studies mea-
sured individual withdrawal signs and an overall opiate withdrawal score was calculated
(Zachariou et al., 2003; Kasanga et al., 2017) which may have prevented us from observing
differences in this current study. Previous studies have used different routes of adminis-
tration of drugs, length of drug administration and different mouse strains (Cichewicz &
Welch, 2003; Rzasa Lynn & Galinkin, 2018). It is worth mentioning that we did not in-
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clude female mice in this withdrawal study. Given that MS15203 showed greater difference
during morphine tolerance in female mice, it is possible that the agonist might show an
effect on morphine withdrawal if tested in female mice. Future studies with different doses
and testing paradigms are needed to rule out that GPR171 is not involved in morphine
withdrawal. Overall, these data suggest that GPR171 agonist, MS15203, can be safely used
as a combination therapy with morphine without worsening morphine withdrawal.
4.1.6 Interactions Between GPR171 and MOPr Systems
All these results support the idea that these two receptors systems work together.
Our previous study reported that antagonism or knockdown of GPR171 reduces MOPr
mediated G protein signaling (McDermott et al., 2019), meaning that GPR171 may be a
regulator of MOPr signaling. This could happen if these two receptors interact by het-
erodimer formation. A number of studies have postulated that several GPCRs form both
homo and heterodimers (Terrillon & Bouvier, 2004; Alfaras-Melainis, 2009). Notably, both
the MOPr and GPR171 have been found to functionally interact with other receptors and
form heterodimers (Fujita, Gomes, & Devi, 2015; Gomes et al., 2016; Margolis, Fujita,
Devi, & Fields, 2017). These receptor–receptor interactions modulate ligand binding and
the signaling properties of the individual receptors (Al-Hasani & Bruchas, 2011; Stockton
& Devi, 2012). It has been previously reported that MOPrs can be modulated by other
receptors. Antinociceptive effects of MOPrs is regulated by the DOPr (Porreca, Mosberg,
Hurst, Hruby, & Burks, 1984; Abul-Husn, Sutak, Milne, & Jhamandas, 2007), cannabinoid
receptors (Cichewicz & McCarthy, 2003), glutamate receptors (Nishiyama, Yaksh, & We-
ber, 1998; M. M. Morgan, Bobeck, & Ingram, 2009), orexin receptors (Azhdari-Zarmehri,
Esmaeili, Sofiabadi, & Haghdoost-Yazdi, 2013; Emam et al., 2016) and alpha-2 adrener-
gic receptor (Drasner & Fields, 1988). We know that GPR171 can interact with another
GPCR, GPR83 (Gomes et al., 2016), but it is unknown whether it dimerizes with the MOPr
as well. Our immunohistochemistry data reports the expression of GPR171 on the GABA
neurons of PAG while it is well known that MOPr are also highly expressed on the GABA
neurons (Bobeck et al., 2014). Activation of these two receptors together will likely inhibit
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GABA release to a greater extent thereby exciting the projection neurons from the PAG to
the RVM (Terwilliger et al., 1991; Lau & Vaughan, 2014; Lueptow et al., 2018). It is also
noteworthy that the GPR171 and MOPr both are inhibitory GPCRs meaning that they are
coupled to Gai/o proteins and inhibit cAMP production (Gomes et al., 2013). When these
two receptors are activated together, there is crosstalk between signaling pathways which
could produce enhanced downstream signaling and greater morphine antinociception. To
our knowledge, this current study is the first to look at this receptor’s role in opioid toler-
ance and withdrawal. Additionally, we are not aware of any previous studies about GPR171
that included both sexes. Our primary focus in this current study was to investigate this
receptor’s function in vivo. Future studies are needed to determine the underlying cellular
changes of these behavioral observations.
4.1.7 Limitations of the Study
Although this research has revealed some exciting findings, there are some unavoidable
limitations that should be noted. One of the limitations of this study is the cumulative
dosing procedure of morphine. In order to complete testing within the antinociceptive
time course of the opioid, only 5 doses of morphine were administered. Previous studies
have shown that using this cumulative dosing paradigm causes higher ED50 values than
a paradigm where dose-response curves are created by testing animals once with only a
particular dose (Kumar et al., 2008; Sirohi, Dighe, Madia, & Yoburn, 2009). However, with
those studies hundreds more animals must be used to get a large enough sample size at each
dose. Furthermore, we investigated only one dose of the agonist, MS15203 (Wardman et al.,
2016). We also used just one specific injection and testing time that were adapted from our
previous studies (Bobeck et al., 2014). Because GPR171 is relatively a new area of research,
there is not enough data available to know the optimal dose and timing of MS15203, thus a
thorough dose-responses and time course of the effectiveness of MS15203 still needs further
exploration. The other problem with this study is that there is an arbitrary tail flick and
hotplate cutoff latency. In receptor binding studies, calculation of EC50s are more precise,
because there is not a given cutoff value (Tallarida, 2000). In the current experiment a cutoff
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value must be used in order to prevent tissue damage of the mouse tail and paw. Another
limitation of this present study is that we performed immunohistochemistry only in male
mice to see the expression of GPR171 in the PAG. Additionally, we have not examined
the phase of estrous cycle of the female mice. It is evident that female shows variability in
morphine tolerance development at different stages of estrous cycle (Shekunova & Bespalov,
2004).
4.1.8 Implications and Future Directions
The findings of this study are an important step for the development of a novel pain
therapeutic particularly for chronic pain with reduced tolerance and dependance than opioid
treatment alone. This study shows that GPR171 agonist, MS15203, does not have any
adverse effects during long term morphine use indicating that MS15203 can be safely used
with morphine for better synergistic analgesic effects. This combination therapy will allow
for a reduction in the dose of morphine thereby reducing tolerance and dependence to
morphine during long-term treatment. Further studies are needed to expand the results of
this study. Our results demonstrate several sex differences in the function of MS15203. This
is the first study that has been conducted on GPR171 that includes female mice. Given
that MS15203 shows female specific attenuation of morphine tolerance, it has the potential
to be used in gender specific drug tailoring. Future studies are needed to interpret the
possible mechanisms underlying sexual dimorphism in the role of GPR171 in regulating the
analgesic effects of morphine. The gender specific population and distribution of GPR171 in
the brain and spinal cord, pharmacokinetics, and neuronal circuitry need to be investigated.
In this present study, we only used a specific dose of MS15203, further studies are warranted
with different does of MS15203 to determine the optimal dose. It is also recommended to
study the effects of chronic MS15203 administration in combination with acute and chronic
morphine treatment to evaluate if there is any cross tolerance between these two drugs. We
investigated the role of GPR171 only in morphine function, the other MOPr agonists should
be evaluated in future. Another important future experiment is to evaluate the function of
GPR171 in other pain models such as inflammatory and neuropathic pain.
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4.2 Conclusion
Collectively, these findings lay the groundwork for future studies aimed at GPR171
function, therefore, making it a novel area of study towards the development of pain ther-
apeutics. Here, we presented that the GPR171 agonist, MS15203, decreases morphine
tolerance in female mice and notably, it does not aggravate morphine induced tolerance
and withdrawal during chronic morphine treatment. Clinically, this would be a beneficial
outcome in reducing opioid dosage, because patients will require smaller doses of the opioid
agonist to produce the same amount of antinociception. The outcome of this study helps to
elucidate the sex differences in GPR171 function and will be an important step to support
sex specific tailoring of pain therapeutics in future.
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Fig. A.1: GPR171 antagonist does not alter morphine tolerance in male mice on the tail
flick and hot plate test. Tolerance was induced by twice-daily injections of morphine for 4
days as seen by a rightward shift in the dose response curve for DMSO + Morphine group
compared to DMSO + Saline group in tail flick (A), but not in the hot plate (B) test. Dose
response curves were performed on Day 5 using a cumulative quarter log dose procedure of
morphine (1, 1.8, 3.2, 5.6, 10, and 18 mg/kg, s.c.). Repeated administration of MS21570 +
Morphine on Day 1-4 did not affect morphine tolerance on the tail flick (A) and hot plate
(B) test. The data reveals that morphine tolerance is not affected by GPR171 antagonist
in male mice. 5-9 animals/group.
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Fig. B.1: GPR171 antagonist does not alter morphine withdrawal. Animals were treated
with GPR171 antagonist, MS21570 (5 mg/kg, i.p.) or vehicle (10% DMSO in saline, i.p.)
10 minutes before morphine (5 mg/kg, s.c.) or saline (10 ml/kg, s.c.) injection twice daily
for 4 days to induce morphine dependence. On day 5, mice were treated with their des-
ignated drug combination. Two hours later Naloxone Hydrochloride (2 mg/kg, i.p.) was
administered to induce precipitated withdrawal. Mice were video recorded immediately for
30 minutes to observe withdrawal behavior- jumping. Repeated injection of DMSO + Mor-
phine caused an increase in jumping number compared to the DMSO + Saline treated mice
indicating that those mice developed morphine dependence. Pretreatment with MS21570 +
Morphine reduced jumping number compared to the DMSO + Morphine group, although
the reduction is not significant. Repeated injection of MS21570 + Saline increased the jump-
ing number compared to the DMSO + Saline group, although not significant. *P < 0.05,
compared with saline; #P < 0.05, compared with morphine. Data are the means ±SEM.
9–10 animals/group.
